Evidence map›Paper›PMID 33094284›Full record

ArticleBrain communications2020

Principal component analysis, a useful tool to study cyclin-dependent kinase-inhibitor's effect on cerebral ischaemia.

Lucas Le Roy, Ahmed Amara, Cloé Le Roux, Ozvan Bocher, Anne Létondor, Nathalie Benz, Serge Timsit

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lucas Le RoyUniv Brest, Inserm, EFS, UMR 1078, Genetics, functional genomics and biotechnology (GGB), F-29200, Brest, France.
Ahmed AmaraUniv Brest, Inserm, EFS, UMR 1078, Genetics, functional genomics and biotechnology (GGB), F-29200, Brest, France.
Cloé Le RouxUniv Brest, Inserm, EFS, UMR 1078, Genetics, functional genomics and biotechnology (GGB), F-29200, Brest, France.
Ozvan BocherUniv Brest, Inserm, EFS, UMR 1078, Genetics, functional genomics and biotechnology (GGB), F-29200, Brest, France.
Anne LétondorUniv Brest, Inserm, EFS, UMR 1078, Genetics, functional genomics and biotechnology (GGB), F-29200, Brest, France.
Nathalie BenzUniv Brest, Inserm, EFS, UMR 1078, Genetics, functional genomics and biotechnology (GGB), F-29200, Brest, France.
Serge TimsitUniv Brest, Inserm, EFS, UMR 1078, Genetics, functional genomics and biotechnology (GGB), F-29200, Brest, France.ORCID 0000-0003-0346-8576
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a leading cause of acute death related in part to brain oedema, blood-brain barrier disruption and glial inflammation. A cyclin-dependant kinase inhibitor, (S)-roscovitine, was administered 90 min after onset on a model of rat focal cerebral ischaemia. Brain swelling and Evans Blue tissue extravasation were quantified after Evans Blue injection. Combined tissue Evans Blue fluorescence and immunofluorescence of endothelial cells (RECA1), microglia (isolectin-IB4) and astrocytes (glial fibrillary acidic protein) were analysed. Using a Student's

Indexed as

CDK inhibitorischaemic strokeNeuroVascular Unitoedema

Identifiers

PMID33094284
PMCPMC7566348
OpenAlexW3082942093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.